81 related articles for article (PubMed ID: 19123459)
1. Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies.
Díez-Campelo M; Pérez-Simón JA; Pérez J; Alcoceba M; Richtmon J; Vidriales B; San Miguel J
Am J Hematol; 2009 Mar; 84(3):149-52. PubMed ID: 19123459
[TBL] [Abstract][Full Text] [Related]
2. Identification and surveillance of rare relapse-initiating stem cells during complete remission after transplantation.
Dimitriou M; Mortera-Blanco T; Tobiasson M; Mazzi S; Lehander M; Högstrand K; Karimi M; Walldin G; Jansson M; Vonlanthen S; Ljungman P; Langemeijer S; Yoshizato T; Hellström-Lindberg E; Woll PS; Jacobsen SEW
Blood; 2024 Mar; 143(11):953-966. PubMed ID: 38096358
[TBL] [Abstract][Full Text] [Related]
3. Peri-transplant flow-MRD assessment of cells with leukemic stem cells (LSC) associated phenotype in AML patients undergoing allogeneic stem cell transplantation in CR.
Klyuchnikov E; Badbaran A; Massoud R; Freiberger P; Wolschke C; Ayuk F; Fehse B; Bacher U; Kröger N
Leukemia; 2024 Feb; 38(2):386-388. PubMed ID: 38263432
[No Abstract] [Full Text] [Related]
4. Measurable residual disease monitoring by ddPCR in the early posttransplant period complements the traditional MFC method to predict relapse after HSCT in AML/MDS: a multicenter retrospective study.
Chen W; Huang J; Zhao Y; Huang L; Yuan Z; Gu M; Xu X; Shi J; Luo Y; Yu J; Lai X; Liu L; Fu H; Bao C; Huang X; Zheng Z; Huang H; Hu X; Zhao Y
J Transl Med; 2024 Apr; 22(1):410. PubMed ID: 38689269
[TBL] [Abstract][Full Text] [Related]
5. Measurable Residual Disease and Clonal Evolution in Acute Myeloid Leukemia from Diagnosis to Post-Transplant Follow-Up: The Role of Next-Generation Sequencing.
Sperotto A; Bochicchio MT; Simonetti G; Buccisano F; Peccatori J; Piemontese S; Calistri E; Ciotti G; Pierdomenico E; De Marchi R; Ciceri F; Gottardi M
Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830896
[TBL] [Abstract][Full Text] [Related]
6. Genetics of progression from MDS to secondary leukemia.
Menssen AJ; Walter MJ
Blood; 2020 Jul; 136(1):50-60. PubMed ID: 32430504
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for acute myeloid leukemia: from allogeneic stem cell transplant to novel therapeutics.
Knorr DA; Goldberg AD; Stein EM; Tallman MS
Leuk Lymphoma; 2019 Dec; 60(14):3350-3362. PubMed ID: 31335250
[TBL] [Abstract][Full Text] [Related]
8. Mutation Clearance after Transplantation for Myelodysplastic Syndrome.
Duncavage EJ; Jacoby MA; Chang GS; Miller CA; Edwin N; Shao J; Elliott K; Robinson J; Abel H; Fulton RS; Fronick CC; O'Laughlin M; Heath SE; Brendel K; Saba R; Wartman LD; Christopher MJ; Pusic I; Welch JS; Uy GL; Link DC; DiPersio JF; Westervelt P; Ley TJ; Trinkaus K; Graubert TA; Walter MJ
N Engl J Med; 2018 Sep; 379(11):1028-1041. PubMed ID: 30207916
[TBL] [Abstract][Full Text] [Related]
9. [How I manage minimal residual disease positive patients with acute leukemia who underwent allogeneic stem cell transplantation].
Chang YJ; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):448-453. PubMed ID: 30032558
[No Abstract] [Full Text] [Related]
10. MRD in AML: does it already guide therapy decision-making?
Ossenkoppele G; Schuurhuis GJ
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):356-365. PubMed ID: 27913502
[TBL] [Abstract][Full Text] [Related]
11. Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT.
Tsirigotis P; Byrne M; Schmid C; Baron F; Ciceri F; Esteve J; Gorin NC; Giebel S; Mohty M; Savani BN; Nagler A
Bone Marrow Transplant; 2016 Nov; 51(11):1431-1438. PubMed ID: 27295272
[TBL] [Abstract][Full Text] [Related]
12. Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia.
Zeijlemaker W; Kelder A; Oussoren-Brockhoff YJ; Scholten WJ; Snel AN; Veldhuizen D; Cloos J; Ossenkoppele GJ; Schuurhuis GJ
Leukemia; 2016 Mar; 30(3):708-15. PubMed ID: 26373238
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of treating post-transplantation minimal residual disease in children with acute leukemia.
Shah NN; Borowitz MJ; Robey NC; Gamper CJ; Symons HJ; Loeb DM; Wayne AS; Chen AR
Biol Blood Marrow Transplant; 2014 Jul; 20(7):1000-7. PubMed ID: 24680975
[TBL] [Abstract][Full Text] [Related]
14. Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML.
Anthias C; Dignan FL; Morilla R; Morilla A; Ethell ME; Potter MN; Shaw BE
Bone Marrow Transplant; 2014 May; 49(5):679-83. PubMed ID: 24510069
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease as a predictive factor for relapse after allogeneic hematopoietic stem cell transplant in adult patients with acute myeloid leukemia in first and second complete remission.
Grubovikj RM; Alavi A; Koppel A; Territo M; Schiller GJ
Cancers (Basel); 2012 Jun; 4(2):601-17. PubMed ID: 24213327
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how?
Gyurkocza B; Deeg HJ
Blood Rev; 2012 Nov; 26(6):247-54. PubMed ID: 22981712
[TBL] [Abstract][Full Text] [Related]
17. Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges.
Shah NN; Bacher U; Fry T; Calvo KR; Stetler-Stevenson M; Arthur DC; Kurlander R; Baird K; Wise B; Giralt S; Bishop M; Hardy NM; Wayne AS
Am J Hematol; 2012 Sep; 87(9):916-22. PubMed ID: 22473867
[No Abstract] [Full Text] [Related]
18. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.
Walter RB; Gooley TA; Wood BL; Milano F; Fang M; Sorror ML; Estey EH; Salter AI; Lansverk E; Chien JW; Gopal AK; Appelbaum FR; Pagel JM
J Clin Oncol; 2011 Mar; 29(9):1190-7. PubMed ID: 21282535
[TBL] [Abstract][Full Text] [Related]
19. Relapse after allogeneic stem cell transplantation.
Barrett AJ; Battiwalla M
Expert Rev Hematol; 2010 Aug; 3(4):429-41. PubMed ID: 21083034
[TBL] [Abstract][Full Text] [Related]
20. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes.
Kröger N; Bacher U; Bader P; Böttcher S; Borowitz MJ; Dreger P; Khouri I; Macapinlac HA; Olavarria E; Radich J; Stock W; Vose JM; Weisdorf D; Willasch A; Giralt S; Bishop MR; Wayne AS
Biol Blood Marrow Transplant; 2010 Sep; 16(9):1187-211. PubMed ID: 20558311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
